VistaGen Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by VistaGen Therapeutics, Inc. on September 4, 2014, covering events occurring on September 2, 2014. The filing details a material definitive agreement regarding the company's debt obligations.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, or cash flow data. The only specific financial metric disclosed is the aggregate outstanding balance of Senior Secured Convertible Promissory Notes held by Platinum Long Term Growth VII, LLC, which is approximately $4.2 million (including principal and accrued interest).
Material Changes
On September 2, 2014, the Company entered into Amendment No. 1 to the Amended and Restated Note Conversion Agreement and Warrant Amendment with Platinum Long Term Growth VII, LLC. This amendment modifies the terms of an agreement originally executed on July 18, 2014. Under the new terms, Platinum has agreed to convert the entire $4.2 million debt balance into equity securities if the Company meets specific financing milestones by September 30, 2014.
Guidance, Outlook, and Contingencies
The conversion of debt to equity is contingent upon the Company completing one of the following financing transactions by September 30, 2014:
- A private equity financing resulting in gross proceeds of at least $36.0 million; or
- A public common stock financing transaction resulting in gross proceeds of at least $10.0 million pursuant to an effective SEC registration statement.
The filing does not provide management commentary on future revenue guidance or operational outlook beyond these financing conditions.
Investor Verification Checklist
- Verify the full text of Amendment No. 1 (Exhibit 10.1) for specific conversion pricing and warrant terms.
- Confirm whether the Company successfully raised the required $36.0 million (private) or $10.0 million (public) by the September 30, 2014 deadline.
- Review the July 22, 2014 Form 8-K to understand the original debt agreement terms prior to this amendment.
- Monitor subsequent filings for the actual issuance of equity shares if the financing conditions were met.